

Amitava Banerjee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1792636/publications.pdf>

Version: 2024-02-01

200
papers

64,543
citations

28274

55
h-index

3182

186
g-index

231
all docs

231
docs citations

231
times ranked

100595
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 vaccination uptake amongst ethnic minority communities in England: a linked study exploring the drivers of differential vaccination rates. <i>Journal of Public Health</i> , 2023, 45, e65-e74.	1.8	26
2	Hospitalization for Heart Failure in the United States, UK, Taiwan, and Japan: An International Comparison of Administrative Health Records on 413,385 Individual Patients. <i>Journal of Cardiac Failure</i> , 2022, 28, 353-366.	1.7	11
3	Understanding and tracking the impact of long COVID in the United Kingdom. <i>Nature Medicine</i> , 2022, 28, 11-15.	30.7	19
4	A population-based study of 92 clinically recognized risk factors for heart failure: co-occurrence, prognosis and preventive potential. <i>European Journal of Heart Failure</i> , 2022, 24, 466-480.	7.1	14
5	Technology-Enabled, Evidence-Driven, and Patient-Centered: The Way Forward for Regulating Software as a Medical Device. <i>JMIR Medical Informatics</i> , 2022, 10, e34038.	2.6	4
6	A population-based cohort study of obesity, ethnicity and COVID-19 mortality in 12.6 million adults in England. <i>Nature Communications</i> , 2022, 13, 624.	12.8	29
7	Lifetime risk of cardiovascular-renal disease in type 2 diabetes: a population-based study in 473,399 individuals. <i>BMC Medicine</i> , 2022, 20, 63.	5.5	10
8	Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1277-1287.	4.4	15
9	Long COVID and cardiovascular disease: a learning health system approach. <i>Nature Reviews Cardiology</i> , 2022, 19, 287-288.	13.7	17
10	Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort. <i>Heart</i> , 2022, 108, 923-931.	2.9	12
11	Smartphone detection of atrial fibrillation using photoplethysmography: a systematic review and meta-analysis. <i>Heart</i> , 2022, 108, 1600-1607.	2.9	15
12	Admission Blood Glucose Level and Its Association With Cardiovascular and Renal Complications in Patients Hospitalized With COVID-19. <i>Diabetes Care</i> , 2022, 45, 1132-1140.	8.6	4
13	Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19. <i>Heart</i> , 2022, 108, 1200-1208.	2.9	10
14	Frameworks for Implementation, Uptake, and Use of Cardiometabolic Disease-Related Digital Health Interventions in Ethnic Minority Populations: Scoping Review. <i>JMIR Cardio</i> , 2022, 6, e37360.	1.7	4
15	The Impact of COVID Vaccination on Symptoms of Long COVID: An International Survey of People with Lived Experience of Long COVID. <i>Vaccines</i> , 2022, 10, 652.	4.4	59
16	Indirect effects of the pandemic: highlighting the need for data-driven policy and preparedness. <i>Journal of the Royal Society of Medicine</i> , 2022, 115, 249-251.	2.0	7
17	Variation in revascularisation use and outcomes of patients in hospital with acute myocardial infarction across six high income countries: cross sectional cohort study. <i>BMJ, The</i> , 2022, 377, e069164.	6.0	13
18	Strategies to record and use ethnicity information in routine health data. <i>Nature Medicine</i> , 2022, 28, 1338-1342.	30.7	31

#	ARTICLE	IF	CITATIONS
19	Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study. <i>Global Heart</i> , 2022, 17, .	2.3	12
20	Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a <scp>UK</scp> clinical setting: An observational outcomes study based on international guidelines for kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2138-2147.	4.4	4
21	A retrospective cohort study predicting and validating impact of the COVID-19 pandemic in individuals with chronic kidney disease. <i>Kidney International</i> , 2022, 102, 652-660.	5.2	17
22	Valvular heart disease in the community: the unknown knowns in electronic health record coding. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 616-617.	4.0	0
23	Digital health interventions and inequalities: the case for a new paradigm. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 77-78.	3.5	11
24	Impact of COVID-19 on cardiac procedure activity in England and associated 30-day mortality. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 247-256.	4.0	54
25	Ensemble learning for poor prognosis predictions: A case study on SARS-CoV-2. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021, 28, 791-800.	4.4	6
26	Socio-Economic Burden of Myocardial Infarction Among Cancer Patients. <i>American Journal of Cardiology</i> , 2021, 141, 16-22.	1.6	3
27	The need for improved collection and coding of ethnicity in health research. <i>Journal of Public Health</i> , 2021, 43, e270-e272.	1.8	30
28	Lower cardiorenal risk with <scp>sodium-glucose</scp> cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 75-85.	4.4	43
29	Estimating the Effect of Reduced Attendance at Emergency Departments for Suspected Cardiac Conditions on Cardiac Mortality During the COVID-19 Pandemic. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007085.	2.2	18
30	A Sustainable Community-Based Model of Noncommunicable Disease Risk Factor Surveillance (Shraddha-Jagrithi Project): Protocol for a Cohort Study. <i>JMIR Research Protocols</i> , 2021, 10, e27299.	1.0	3
31	World Heart Federation Roadmap on Atrial Fibrillation – A 2020 Update. <i>Global Heart</i> , 2021, 16, 41.	2.3	39
32	Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1599-1609.	1.8	93
33	Paying for better care?. <i>Lancet Regional Health - Europe</i> , The, 2021, 1, 100010.	5.6	0
34	Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. <i>BMJ</i> , The, 2021, 372, n693.	6.0	494
35	Ethnicity, household composition and COVID-19 mortality: a national linked data study. <i>Journal of the Royal Society of Medicine</i> , 2021, 114, 182-211.	2.0	69
36	Linked electronic health records for research on a nationwide cohort of more than 54 million people in England: data resource. <i>BMJ</i> , The, 2021, 373, n826.	6.0	98

#	ARTICLE	IF	CITATIONS
37	Performance of universal early warning scores in different patient subgroups and clinical settings: a systematic review. <i>BMJ Open</i> , 2021, 11, e045849.	1.9	12
38	Machine learning for subtype definition and risk prediction in heart failure, acute coronary syndromes and atrial fibrillation: systematic review of validity and clinical utility. <i>BMC Medicine</i> , 2021, 19, 85.	5.5	33
39	Predicting endoscopic activity recovery in England after COVID-19: a national analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 381-390.	8.1	40
40	Ethnic differences in COVID-19 mortality during the first two waves of the Coronavirus Pandemic: a nationwide cohort study of 29 million adults in England. <i>European Journal of Epidemiology</i> , 2021, 36, 605-617.	5.7	66
41	Understanding Race and Ethnicity in Cancer and CV Disease. <i>JACC: CardioOncology</i> , 2021, 3, 335-337.	4.0	2
42	Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 419-426.	11.4	158
43	Long-term monitoring in primary care for chronic kidney disease and chronic heart failure: a multi-method research programme. <i>Programme Grants for Applied Research</i> , 2021, 9, 1-218.	1.0	1
44	Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2207-2214.	4.4	22
45	Estimation of the economic burden of COVID-19 using disability-adjusted life years (DALYs) and productivity losses in Kerala, India: a model-based analysis. <i>BMJ Open</i> , 2021, 11, e049619.	1.9	20
46	World Heart Day 2021: COVID-19, digital health, and tackling cardiovascular disease. <i>Lancet</i> , 2021, 398, 1467-1468.	13.7	12
47	Identifying adults at high-risk for change in weight and BMI in England: a longitudinal, large-scale, population-based cohort study using electronic health records. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 681-694.	11.4	37
48	Ethnic-minority groups in England and Wales—factors associated with the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking census and death records. <i>International Journal of Epidemiology</i> , 2021, 49, 1951-1962.	1.9	41
49	Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. <i>BMJ Open</i> , 2021, 11, e048391.	1.9	341
50	Focused action is required to protect ethnic minority populations from COVID-19 post-lockdown. <i>British Journal of General Practice</i> , 2021, 71, 37-40.	1.4	8
51	An informatics consult approach for generating clinical evidence for treatment decisions. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 281.	3.0	8
52	“What is the risk to me from COVID-19?”: Public involvement in providing mortality risk information for people with “high-risk” conditions for COVID-19 (OurRisk.CoV). <i>Clinical Medicine</i> , 2021, 21, e620-e628.	1.9	5
53	Post-COVID-19 assessment in a specialist clinical service: a 12-month, single-centre, prospective study in 1325 individuals. <i>BMJ Open Respiratory Research</i> , 2021, 8, e001041.	3.0	57
54	Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. <i>Heart</i> , 2020, 106, 119-126.	2.9	76

#	ARTICLE	IF	CITATIONS
55	Temporal trends in the incidence, treatment patterns, and outcomes of coronary artery disease and peripheral artery disease in the UK, 2006–2015. <i>European Heart Journal</i> , 2020, 41, 1636-1649.	2.2	36
56	Monitoring indirect impact of COVID-19 pandemic on services for cardiovascular diseases in the UK. <i>Heart</i> , 2020, 106, 1890-1897.	2.9	90
57	Cardiovascular disease in homeless versus housed individuals: a systematic review of observational and interventional studies. <i>Heart</i> , 2020, 106, 1483-1488.	2.9	31
58	Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study. <i>BMJ Open</i> , 2020, 10, e043828.	1.9	233
59	Prevalence, incidence, and outcomes across cardiovascular diseases in homeless individuals using national linked electronic health records. <i>European Heart Journal</i> , 2020, 41, 4011-4020.	2.2	25
60	Epidemiology and treatment of atrial fibrillation in patients with type 2 diabetes in the UK, 2001–2016. <i>Scientific Reports</i> , 2020, 10, 12468.	3.3	7
61	<p>Validity of Acute Cardiovascular Outcome Diagnoses Recorded in European Electronic Health Records: A Systematic Review</p>. <i>Clinical Epidemiology</i> , 2020, Volume 12, 1095-1111.	3.0	23
62	Models for mortality require tailoring in the context of the COVID-19 pandemic – Authors' reply. <i>Lancet</i> , The, 2020, 396, 883-884.	13.7	0
63	What was right about Kerala’s response to the COVID-19 pandemic?. <i>BMJ Global Health</i> , 2020, 5, e003212.	4.7	39
64	Clinical academic research in the time of Corona: A simulation study in England and a call for action. <i>PLoS ONE</i> , 2020, 15, e0237298.	2.5	8
65	Ethnicity, heart failure and the prevention continuum: time to act. <i>Heart</i> , 2020, 106, 631-633.	2.9	2
66	Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1607-1618.	4.4	118
67	Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. <i>Lancet</i> , The, 2020, 395, 1715-1725.	13.7	412
68	Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. <i>The Lancet Global Health</i> , 2020, 8, e1003-e1017.	6.3	760
69	Machine learning: a long way from implementation in cardiovascular disease. <i>Heart</i> , 2020, 106, 318-320.	2.9	5
70	Yoga-Based Cardiac Rehabilitation After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1551-1561.	2.8	55
71	Mitigating lockdown challenges in response to COVID-19 in Sub-Saharan Africa. <i>International Journal of Infectious Diseases</i> , 2020, 96, 308-310.	3.3	40
72	Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. <i>European Heart Journal</i> , 2020, 41, 1132-1140.	2.2	50

#	ARTICLE	IF	CITATIONS
73	Non-communicable diseases awareness and control in a rural population in an epidemiologically advanced stage of transition (Kerala): results of the epidemiology of non-communicable diseases in rural areas study. International Journal of Community Medicine and Public Health, 2020, 7, 2628.	0.1	2
74	Improving the digital health of the workforce in the COVID-19 context: an opportunity to future-proof medical training. Future Healthcare Journal, 2020, 7, 189-192.	1.4	19
75	Gender and ethnic differences in publication of BMJ letters to the editor: an observational study using machine learning. BMJ Open, 2020, 10, e037269.	1.9	7
76	Title is missing!. , 2020, 15, e0237298.		0
77	Title is missing!. , 2020, 15, e0237298.		0
78	Title is missing!. , 2020, 15, e0237298.		0
79	Title is missing!. , 2020, 15, e0237298.		0
80	Subtypes of atrial fibrillation with concomitant valvular heart disease derived from electronic health records: phenotypes, population prevalence, trends and prognosis. Europace, 2019, 21, 1776-1784.	1.7	22
81	UK phenomics platform for developing and validating electronic health record phenotypes: CALIBER. Journal of the American Medical Informatics Association: JAMIA, 2019, 26, 1545-1559.	4.4	143
82	Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis. BMJ Open, 2019, 9, e030596.	1.9	12
83	Biomagnification characteristics and health risk assessment of the neurotoxin BMAA in freshwater aquaculture products of Taihu Lake Basin, China. Chemosphere, 2019, 229, 332-340.	8.2	17
84	Health informatics competencies in postgraduate medical education and training in the UK: a mixed methods study. BMJ Open, 2019, 9, e025460.	1.9	43
85	Global health competencies in UK postgraduate medical training: a scoping review and curricular content analysis. BMJ Open, 2019, 9, e027577.	1.9	8
86	Validity of acute cardiovascular outcome diagnoses in European electronic health records: a systematic review protocol. BMJ Open, 2019, 9, e031373.	1.9	1
87	Bleeding in cardiac patients prescribed antithrombotic drugs: electronic health record phenotyping algorithms, incidence, trends and prognosis. BMC Medicine, 2019, 17, 206.	5.5	12
88	There may be a role for addition of rivaroxaban to aspirin in patients with stable coronary artery disease. BMJ Evidence-Based Medicine, 2019, 24, 78-79.	3.5	0
89	India and the United Kingdomâ€”What big data health research can do for a country. Learning Health Systems, 2019, 3, e10074.	2.0	2
90	The Health Impact Fund: How Might It Work for Novel Anticoagulants in Atrial Fibrillation?. Global Heart, 2019, 9, 255.	2.3	2

#	ARTICLE	IF	CITATIONS
91	Effect of propionamide on the growth of <i>Microcystis flos-aquae</i> colonies and the underlying physiological mechanisms. <i>Science of the Total Environment</i> , 2018, 630, 526-535.	8.0	22
92	Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis. <i>Global Health Action</i> , 2018, 11, 1434935.	1.9	3
93	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 2091-2138.	13.7	335
94	Essential components in natriuretic peptide-guided management of heart failure: an intervention synthesis. <i>Open Heart</i> , 2018, 5, e000826.	2.3	2
95	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 391, 2236-2271.	13.7	638
96	Current computational trends in polyanionic cathode materials for Li and Na batteries. <i>Journal of Physics Condensed Matter</i> , 2018, 30, 283003.	1.8	13
97	Cardiovascular Diseases in India Compared With the United States. <i>Journal of the American College of Cardiology</i> , 2018, 72, 79-95.	2.8	76
98	Can the NHS be a learning healthcare system in the age of digital technology?. <i>BMJ Evidence-Based Medicine</i> , 2018, 23, 161-165.	3.5	6
99	Cardiotoxicity: precision medicine with imprecise definitions. <i>Open Heart</i> , 2018, 5, e000774.	2.3	33
100	Antithrombotic Therapy for Atrial Fibrillation. <i>Chest</i> , 2018, 154, 1121-1201.	0.8	718
101	Exploring the Barriers to and Facilitators of Using Evidence-Based Drugs in the Secondary Prevention of Cardiovascular Diseases: Findings From a Multistakeholder, Qualitative Analysis. <i>Global Heart</i> , 2018, 13, 27.	2.3	13
102	Personalized survival predictions via Trees of Predictors: An application to cardiac transplantation. <i>PLoS ONE</i> , 2018, 13, e0194985.	2.5	40
103	Potential for mobile health (mHealth) prevention of cardiovascular diseases in Kerala: A population-based survey. <i>Indian Heart Journal</i> , 2017, 69, 182-199.	0.5	17
104	Designing strategies to tune reduction potential of organic molecules for sustainable high capacity battery application. <i>Journal of Materials Chemistry A</i> , 2017, 5, 4430-4454.	10.3	61
105	Global Cardiovascular and Renal Outcomes of Reduced GFR. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2167-2179.	6.1	194
106	Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1-25.	2.8	2,705
107	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017, 390, 231-266.	13.7	480
108	Health Effects of Overweight and Obesity in 195 Countries over 25 Years. <i>New England Journal of Medicine</i> , 2017, 377, 13-27.	27.0	5,014

#	ARTICLE	IF	CITATIONS
109	Smoking prevalence and attributable disease burden in 195 countries and territories, 1990â€“2015: a systematic analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017, 389, 1885-1906.	13.7	1,281
110	Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors. <i>European Heart Journal</i> , 2017, 38, 1048-1055.	2.2	44
111	Health informatics in UK Medical Education: an online survey of current practice. <i>JRSM Open</i> , 2017, 8, 205427041668267.	0.5	19
112	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1211-1259.	13.7	5,578
113	Bridging the Global Digital Health Divide for Cardiovascular Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	5
114	Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Card3aca y Electrofisiolog3a (SOLAECE). <i>Europace</i> , 2017, 19, 1589-1623.	1.7	208
115	Using patient data for patientsâ€™ benefit. <i>BMJ: British Medical Journal</i> , 2017, 358, j4413.	2.3	4
116	Challenges for learning health systems in the NHS. Case study: electronic health records in cardiology. <i>Future Hospital Journal</i> , 2017, 4, 193-197.	0.2	4
117	Are cardiovascular risk factors also associated with the incidence of atrial fibrillation?. <i>Thrombosis and Haemostasis</i> , 2017, 117, 837-850.	3.4	128
118	The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation. <i>Global Heart</i> , 2017, 12, 273.	2.3	35
119	Atrial fibrillation: the current epidemic. <i>Journal of Geriatric Cardiology</i> , 2017, 14, 195-203.	0.2	208
120	Global, regional, and national levels of maternal mortality, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1775-1812.	13.7	740
121	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1603-1658.	13.7	1,612
122	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1459-1544.	13.7	4,934
123	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1545-1602.	13.7	5,298
124	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1725-1774.	13.7	571
125	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1813-1850.	13.7	413
126	Stable coronary disease: Cinderella must go to the ball. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016, 2, 151-152.	4.0	0

#	ARTICLE	IF	CITATIONS
127	Health system barriers and facilitators to medication adherence for the secondary prevention of cardiovascular disease: a systematic review. <i>Open Heart</i> , 2016, 3, e000438.	2.3	36
128	Drugs for cardiovascular disease in India: perspectives of pharmaceutical executives and government officials on access and development-a qualitative analysis. <i>Journal of Pharmaceutical Policy and Practice</i> , 2016, 9, 16.	2.4	5
129	Net clinical benefit of edoxaban versus no treatment in a “real world” atrial fibrillation population: A modelling analysis based on a nationwide cohort study. <i>International Journal of Cardiology</i> , 2015, 201, 693-698.	1.7	18
130	Age-specific incidence, risk factors and outcome of acute abdominal aortic aneurysms in a defined population. <i>British Journal of Surgery</i> , 2015, 102, 907-915.	0.3	98
131	Potential for the use of mHealth in the management of cardiovascular disease in Kerala: a qualitative study. <i>BMJ Open</i> , 2015, 5, e009367-e009367.	1.9	45
132	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 743-800.	13.7	4,951
133	Poverty, development and cardiovascular trials: More questions than answers?. <i>Heart</i> , 2015, 101, 245-247.	2.9	2
134	Increased Stroke Risk in Atrial Fibrillation Patients With Heart Failure. <i>Stroke</i> , 2015, 46, 608-609.	2.0	11
135	Below the poverty line and non-communicable diseases in Kerala: The Epidemiology of Non-communicable Diseases in Rural Areas (ENDIRA) study. <i>International Journal of Cardiology</i> , 2015, 187, 519-524.	1.7	29
136	Changes in renal function after catheter ablation of atrial fibrillation are associated with CHADS ₂ and CHA ₂ DS ₂ -VASc scores and arrhythmia recurrences. <i>Heart</i> , 2015, 101, 126-131.	2.9	26
137	Changes in health in England, with analysis by English regions and areas of deprivation, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 2257-2274.	13.7	279
138	Aortic dissection in pregnancy in England: an incidence study using linked national databases. <i>BMJ Open</i> , 2015, 5, e008318.	1.9	22
139	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. <i>Lancet, The</i> , 2015, 386, 2145-2191.	13.7	1,544
140	Population-Based Study of Incidence, Risk Factors, Outcome, and Prognosis of Ischemic Peripheral Arterial Events. <i>Circulation</i> , 2015, 132, 1805-1815.	1.6	148
141	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 2287-2323.	13.7	2,184
142	Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 385, 117-171.	13.7	5,847
143	Stroke and Major Bleeding Risk in Elderly Patients Aged ≥75 Years With Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 143-150.	2.0	116
144	Purification effects of two eco-ditch systems on Chinese soft-shelled turtle greenhouse culture wastewater pollution. <i>Environmental Science and Pollution Research</i> , 2014, 21, 5610-5618.	5.3	20

#	ARTICLE	IF	CITATIONS
145	Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 957-979.	13.7	609
146	Prior History of Falls and Risk of Outcomes in Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project. American Journal of Medicine, 2014, 127, 972-978.	1.5	51
147	Contemporary Management of Atrial Fibrillation: What Can Clinical Registries Tell Us About Stroke Prevention and Current Therapeutic Approaches?. Journal of the American Heart Association, 2014, 3, .	3.7	39
148	Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 1005-1070.	13.7	786
149	Early management of atrial fibrillation to prevent cardiovascular complications. European Heart Journal, 2014, 35, 1448-1456.	2.2	190
150	Global, regional, and national prevalence of overweight and obesity in children and adults during 1980â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 766-781.	13.7	9,122
151	Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation. Thrombosis and Haemostasis, 2014, 112, 549-556.	3.4	25
152	A Prospective Study of Estimated Glomerular Filtration Rate and Outcomes in Patients With Atrial Fibrillation. Chest, 2014, 145, 1370-1382.	0.8	66
153	Surveillance of Noncommunicable Diseases by Community Health Workers in Kerala: The Epidemiology of Noncommunicable Diseases in Rural Areas (ENDIRA) Study. Global Heart, 2014, 9, 409.	2.3	23
154	Abstract P362: Surveillance Of Non-Communicable Diseases By Non-Physician Health Workers In Kerala: the Epidemiology of Non-communicable Diseases in Rural Areas (ENDIRA) study. Circulation, 2014, 129, .	1.6	2
155	Renal Impairment and Ischemic Stroke Risk Assessment in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 2079-2087.	2.8	105
156	Is the higher risk of cardiovascular disease amongst South Asian populations linked to abnormalities of haemoglobin? A preliminary case control study. Atherosclerosis, 2013, 226, 198-200.	0.8	3
157	Pattern of atrial fibrillation and risk of outcomes: The Loire Valley Atrial Fibrillation Project. International Journal of Cardiology, 2013, 167, 2682-2687.	1.7	67
158	Letter by Apostolakis et al Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R ₂ CHADS		

#	ARTICLE	IF	CITATIONS
163	Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation. Thrombosis and Haemostasis, 2013, 110, 560-568.	3.4	41
164	Editorial (Heart Failure: The Need for Global Health Perspective). Current Cardiology Reviews, 2013, 9, 97-98.	1.5	10
165	Heart Failure in East Asia. Current Cardiology Reviews, 2013, 9, 112-122.	1.5	72
166	Assessing the Risk of Bleeding in Patients With Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 941-948.	4.8	68
167	What can quality improvement learn from evidence-based medicine?. Journal of the Royal Society of Medicine, 2012, 105, 55-59.	2.0	10
168	Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. European Journal of Heart Failure, 2012, 14, 295-301.	7.1	96
169	Association Between Family Risk of Stroke and Myocardial Infarction With Prevalent Risk Factors and Coexisting Diseases. Stroke, 2012, 43, 974-979.	2.0	11
170	Family history does not predict angiographic localization or severity of coronary artery disease. Atherosclerosis, 2012, 221, 451-457.	0.8	4
171	(13) Genetic variant of CD36 gene is not associated with Cardiovascular risk factors in South Asians. Atherosclerosis, 2012, 223, 531.	0.8	0
172	To the Editor" Adding renal dysfunction to CHA2DS2-VASc improves stroke prediction postcatheter ablation. Heart Rhythm, 2012, 9, e25.	0.7	0
173	A proposal for new clinical concepts in the management of atrial fibrillation. American Heart Journal, 2012, 164, 292-302.e1.	2.7	47
174	Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a "real world" atrial fibrillation population: A modelling analysis based on a nationwide cohort study. Thrombosis and Haemostasis, 2012, 107, 584-589.	3.4	289
175	Improving the diagnosis and prognosis of atrial fibrillation in stroke: quo vadis?. European Journal of Neurology, 2012, 19, 187-188.	3.3	1
176	Diagnostic accuracy of exercise stress testing for coronary artery disease: a systematic review and meta-analysis of prospective studies. International Journal of Clinical Practice, 2012, 66, 477-492.	1.7	99
177	A review of family history of cardiovascular disease: risk factor and research tool. International Journal of Clinical Practice, 2012, 66, 536-543.	1.7	34
178	Tracking global funding for the prevention and control of noncommunicable diseases. Bulletin of the World Health Organization, 2012, 90, 479-479A.	3.3	45
179	Pre and Post-Operative Treatments for Prevention of Atrial Fibrillation after Cardiac Surgery. Mini-Reviews in Medicinal Chemistry, 2012, 12, 1419-1431.	2.4	14
180	Avances incompletos en la estratificación del riesgo de ictus en la fibrilación auricular. Revista Espanola De Cardiologia, 2011, 64, 639-641.	1.2	8

#	ARTICLE	IF	CITATIONS
181	The Improved but Unfinished Business of Stroke Risk Stratification in Atrial Fibrillation. Revista Espanola De Cardiologia (English Ed), 2011, 64, 639-641.	0.6	2
182	Medical student electives: potential for global health?. Lancet, The, 2011, 377, 555.	13.7	12
183	Bleeding risk with oral anticoagulation - new frontiers and new questions. International Journal of Clinical Practice, 2011, 65, 719-721.	1.7	1
184	Anticipating and managing bleeding complications in patients with coronary stents who are receiving dual antiplatelet treatment. BMJ: British Medical Journal, 2011, 343, d4264-d4264.	2.3	9
185	Relative Familial Clustering of Cerebral Versus Coronary Ischemic Events. Circulation: Cardiovascular Genetics, 2011, 4, 390-396.	5.1	17
186	Familial History of Stroke Is Associated With Acute Coronary Syndromes in Women. Circulation: Cardiovascular Genetics, 2011, 4, 9-15.	5.1	32
187	Health is global “ what does that mean for the United Kingdom?. Journal of the Royal Society of Medicine, 2011, 104, 312-314.	2.0	1
188	Looking through the PRISM: New Insights for Young Patients with Atrial Fibrillation and Stroke. Cerebrovascular Diseases, 2011, 32, 383-384.	1.7	0
189	A New Landscape for Stroke Prevention in Atrial Fibrillation. Stroke, 2011, 42, 3316-3322.	2.0	26
190	Intracerebral Hemorrhage and Warfarin. Stroke, 2011, 42, 2383-2384.	2.0	2
191	Medical electives: a chance for international health. Journal of the Royal Society of Medicine, 2010, 103, 6-8.	2.0	21
192	Associations Between Peripheral Artery Disease and Ischemic Stroke. Stroke, 2010, 41, 2102-2107.	2.0	81
193	The Health Impact Fund: incentives for improving access to medicines. Lancet, The, 2010, 375, 166-169.	13.7	72
194	Combination therapy with clopidogrel and proton-pump inhibitors. Lancet, The, 2010, 375, 28.	13.7	2
195	The Health Impact Fund. Lancet, The, 2010, 375, 1693.	13.7	3
196	The Health Impact Fund: a potential solution to inequity in global drug access. Indian Journal of Medical Ethics, 2010, 7, 240-3.	0.4	1
197	Sex-Specific Familial Clustering of Myocardial Infarction in Patients With Acute Coronary Syndromes. Circulation: Cardiovascular Genetics, 2009, 2, 98-105.	5.1	17
198	The developing world in The New England Journal of Medicine. Globalization and Health, 2006, 2, 3.	4.9	29

#	ARTICLE	IF	CITATIONS
199	Long-Term Function After Restorative Proctocolectomy. Diseases of the Colon and Rectum, 2005, 48, 946-951.	1.3	33
200	Differences in Cardiovascular and Renal Outcomes Between Sodium Glucose Co-Transporter-2 and Dipeptidyl Peptidase-4 Inhibitors Among Type 2 Diabetes Patients: A Real-World, Retrospective Cohort Study. SSRN Electronic Journal, 0, , .	0.4	0